COVID-19 Response (VI): DPX-COVID-19 Clinical Development and DPX-CoVLP Proof-of-Concept Study
$3,791,179.00
Grant Value
2021-22
Fiscal Year
Description
In response to the global crisis, IMV has initiated the development of a vaccine to protect against the COVID-19 pandemic. We believe our targeted peptide epitope approach has the potential to optimize and exceed the safety and efficacy profile of more conventional vaccines. DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape, even in case of a virus mutation. Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
ImmunoVaccine Technologies Inc.
Location
Dartmouth, NS B3B 2C4
Agreement Details
Number: 957553
Reference: 172-2021-2022-Q4-957553
Timeline
Start: Sept. 4, 2020
End: Aug. 31, 2022
Program
Industrial Research Assistance Program Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Manufacturing (325410)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share